Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevan...
All content for ACE OncoCast is the property of ACE Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevan...
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 3
ACE OncoCast
21 minutes
1 year ago
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 3
Episode 3: Panel Discussion & Pearls for Practice Aristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhD The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scenarios following progression of 1L therapies. In this educational program on 'Best Practice Exchange in Clinical Case Scenarios', field experts wil...
ACE OncoCast
Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevan...
